Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670–1751.

Classification & Diagnosis

1.1 Types of Hypothyroidism

Type	Definition	Key lab pattern
Primary (thyroidal)	Thyroid gland failure — by far the most common form	TSH ↑, FT4 ↓ (overt) or FT4 normal (subclinical)
Secondary / Central (pituitary or hypothalamic)	Deficient TSH drive from the pituitary/hypothalamus	TSH inappropriately normal/low, FT4 ↓ — TSH is NOT reliable for diagnosis or monitoring
Overt hypothyroidism (OH)	Biochemically unambiguous thyroid hormone deficiency	TSH above reference range AND FT4 below reference range
Subclinical hypothyroidism (SCH)	Mild thyroid failure, compensated by pituitary	TSH above reference range, FT4 WITHIN reference range

ATA 1b/rec.20b: In primary hypothyroidism, serum TSH is the best marker of thyroid status and the basis for LT4 dosing. In secondary (central) hypothyroidism, TSH cannot be used — dosing is instead guided by serum FT4 (target: mid-to-upper reference range), since TSH may stay undetectable even when the patient is still hypothyroid.

1.2 Reference Ranges / Diagnostic Cut-offs

Population	TSH target/reference	Notes
General adult reference range	0.4–4.0 mIU/L	Standard treatment target for primary OH (ATA 1b)
Elderly (esp. >70–80y)	Reference range shifts upward with age; 97.5th percentile ≈7.5 mIU/L in healthy elderly	Higher TSH targets are appropriate; avoid over-treatment (ATA 6a)
Pregnancy — 1st trimester	0.1–2.5 mIU/L	Trimester-specific ranges per ATA pregnancy guideline (ATA 6b)
Pregnancy — 2nd trimester	0.2–3.0 mIU/L
Pregnancy — 3rd trimester	0.3–3.0 mIU/L
Overtreatment threshold (caution)	TSH < 0.1 mIU/L	Associated with atrial fibrillation & fracture risk, esp. elderly/postmenopausal women (ATA 4c)
SCH — treat vs monitor	TSH >10 mIU/L: treatment reasonable. TSH ≤10 (mild SCH): individualize	Cardiovascular mortality/morbidity signal chiefly seen at TSH >10, possibly >7 mIU/L (ATA discussion 1b)

1.3 Symptoms & Clinical Assessment — Reliability

ATA 1c: Clinical symptoms (cold intolerance, dry skin, etc.) lack sensitivity and specificity and are NOT recommended for judging adequacy of LT4 replacement in the absence of biochemical (TSH) assessment. Achilles reflex time has a reported sensitivity of 77% and specificity of 93% but is not a routine clinical tool.

ATA 1d: Tissue biomarkers of thyroid hormone action (voice frequency, basal metabolic rate, lipid changes, etc.) are NOT recommended for routine clinical use — not sensitive, specific, standardized, or readily available.

Not detailed in the 2014 ATA guideline (general medical knowledge, included for context): A classic symptom list is commonly taught (fatigue, cold intolerance, weight gain, constipation, dry/coarse skin, hair thinning, bradycardia, non-pitting edema/myxedema, hoarse voice, menstrual irregularity, depression, cognitive slowing, myalgia). The ATA guideline deliberately does not rely on these for diagnosis/monitoring — use them only to raise suspicion, then confirm biochemically.

💡 Clinical Pearls — Diagnosis
– TSH is king in primary hypothyroidism — it is both the diagnostic test and the monitoring parameter.
– Symptoms alone should never drive a dose change.
– If TSH and the clinical picture don’t match (e.g., normal TSH but the patient still looks hypothyroid, or high TSH with a pituitary/hypothalamic history) — suspect central hypothyroidism and switch to FT4-based monitoring.
– SCH is a grey zone: TSH >10 mIU/L generally warrants treatment; TSH ≤10 requires individualized risk-benefit assessment.

1.4 Genomics / Pharmacogenomics

Deiodinase (DIO) gene polymorphisms have been studied for their effect on LT4 dose requirements and T4/T3 conversion:

• DIO2-Thr92Ala polymorphism: conflicting data — one study linked the homozygous Ala/Ala form to higher LT4 requirement post-thyroidectomy; a subsequent study found no effect on LT4 dose needed for TSH normalization in Hashimoto’s or thyroid cancer patients.
• DIO2-258A/G (D2-ORFa-Gly3Asp) polymorphism: associated with lower serum T4/FT4 and a weaker FT4-TSH negative feedback relationship, but clinical significance remains unproven.
• DIO1 polymorphisms (e.g., rs2235544, C785T): small, statistically significant but clinically marginal effects on circulating T3/rT3.
• MCT8 mutations (hemizygous males): cause Allan-Herndon-Dudley syndrome — severe psychomotor retardation with a distinct pattern of ↑T3, ↓T4, mildly ↑TSH. This is a distinct genetic syndrome, not typical adult hypothyroidism.

ATA Section VII discussion: Given the limited and inconsistent data, deiodinase polymorphism testing is NOT part of routine clinical management — genetics may partly explain unusual dose requirements in individual patients but is not an actionable/standard lab.

💡 Clinical Pearls — Genomics
– Don’t order deiodinase genotyping in routine practice — the ATA guideline treats it as investigational, not clinically actionable.
– If a patient needs an unusually high LT4 dose despite good adherence, look first at absorption (drug/food interactions, GI disease) before attributing it to genetics — those causes are far more common and far more treatable.

Etiology & Differential Diagnosis

2.1 Common Etiologies Referenced in the ATA Guideline

The guideline’s clinical trial tables (combination therapy trials) consistently stratify patients by etiology, reflecting the major real-world categories:

• Autoimmune (Hashimoto’s) thyroiditis — most frequently cited etiology across the cited trials
• Post-radioactive iodine (RAI) ablation
• Post-thyroid surgery / post-thyroidectomy
• Post-external beam radiotherapy (EBRT)
• Secondary/central hypothyroidism — pituitary or hypothalamic disease (see Section 1.1)
• Thyroid dysgenesis — most common cause of congenital hypothyroidism (~1:2000–1:4000 newborns) (ATA 6c discussion)

2.2 Important Hospital-Setting Differential: Nonthyroidal Illness Syndrome (NTIS)

ATA 22a/22b: NTIS (“sick euthyroid syndrome”/”low T3 syndrome”) occurs in critically ill patients WITHOUT underlying thyroid disease: T3 falls first, then TSH and/or T4, then FT4 in the sickest patients. This is an adaptive physiologic response, NOT true hypothyroidism, and thyroid hormone replacement is NOT recommended in this setting.

⚠ Pharmacist Watchouts — NTIS vs. true hypothyroidism
– Do not reflexively start or increase levothyroxine for a low TSH/T3 in a critically ill patient with no prior thyroid diagnosis — this is very likely NTIS, and treating it is not evidence-based.
– A patient with PRE-EXISTING hypothyroidism who becomes critically ill should be MAINTAINED on levothyroxine even though they may also show NTIS-type lab changes — a rising TSH in this population usually signals true undertreatment.
– In hospitalized patients about to start/adjust LT4, adrenal insufficiency should be considered/excluded first (ATA 20d) — untreated adrenal insufficiency plus thyroid hormone replacement can precipitate an adrenal crisis.

2.3 Resistance to Thyroid Hormone (RTH) Syndromes

ATA 24a/24b: Genetic syndromes of resistance to thyroid hormone (RTHβ far more common than RTHα) present with elevated free T4/T3 and non-suppressed TSH, and management is highly individualized (goal: tissue-specific correction of thyroid hormone action, sometimes using TRIAC or other analogs in research/specialist settings) — this is a distinct clinical entity from primary hypothyroidism and outside routine LT4 dosing algorithms.

Not detailed in the 2014 ATA guideline (general medical knowledge, included for context): A traditional differential-diagnosis list for a picture that mimics hypothyroidism (e.g., depression, anemia, chronic fatigue syndrome, obstructive sleep apnea, adrenal insufficiency, medication effects such as amiodarone/lithium/interferon-induced thyroid dysfunction) is standard clinical teaching but is not laid out as a differential-diagnosis list in the ATA treatment guideline, which focuses on management once the diagnosis of hypothyroidism is established.

💡 Clinical Pearls — Etiology & Differential
– Etiology matters for dosing: post-RAI/post-thyroidectomy patients are often fully athyreotic and need full weight-based replacement quickly; autoimmune (Hashimoto’s) patients may have residual function and can sometimes be started lower.
– In the ICU, resist the urge to treat abnormal thyroid labs in a patient with no prior thyroid history — get an endocrinology/ID work-up mindset (NTIS) rather than a reflexive LT4 order.

Levothyroxine (LT4) Pharmacotherapy

3.1 Standard of Care

ATA 1a: Levothyroxine (LT4) monotherapy is the standard of care for hypothyroidism.

ATA 23: Thyroid hormone analogs / thyromimetics should NOT be used in euthyroid patients for non-thyroid indications (e.g., dyslipidemia, obesity) outside of research settings — insufficient evidence of benefit, and safety concerns.

⚠ Pharmacist Watchouts — Compounded/alternative therapies
– The ATA explicitly warns against compounded T3 protocols (e.g., “Wilson’s syndrome” temperature protocol) — a documented case of serious iatrogenic T3 thyrotoxicosis (and a reported patient death) resulted from escalating compounded T3 dosing.
– Counsel patients away from these regimens.
– Desiccated thyroid extract (contains both T4 and T3, e.g., porcine-derived) has not been adequately studied long-term; a T4:T3 ratio mismatch relative to physiologic human secretion is a concern.
– It should NOT be used in pregnancy (adequate fetal T4 delivery is critical).

3.2 Starting Dose (Adults)

Patient group	Starting dose	Rationale / ATA basis
Young, healthy, otherwise well	Full weight-based dose: ~1.6 mcg/kg/day (≈0.73 mcg/lb) based on ideal/lean body weight	Full replacement is safe and effective for reaching target faster (ATA 4b)
Mild hypothyroidism / TSH ≤10 mIU/L or SCH	Lower starting dose, e.g., 25–50 mcg/day	Smaller deficit needs less replacement (ATA 4b)
Elderly WITHOUT known cardiovascular disease	Full dose may be used (one RCT showed safety when CV disease excluded by stress testing), but many experts still prefer starting low	“Start low, go slow” remains widely favored absent documented CV clearance (ATA 6a)
Elderly WITH cardiovascular disease / known CAD	Low dose: 12.5–25 mcg/day	Risk of precipitating angina/arrhythmia with abrupt increases in metabolic demand (ATA 4b, 5b)
Post-RAI / post-hyperthyroidism-treatment (recently euthyroid/hyperthyroid)	Exception to “go slow” — can generally start at a fuller dose	Hypothyroidism duration has been brief; less concern for unmasking cardiac disease (ATA 4b)
Pregnancy, pre-existing LT4 use, pregnancy just confirmed	Add 2 extra doses/week (i.e., ~29% dose increase), given as one extra dose twice weekly, several days apart	Anticipates known early pregnancy ↑ requirement (ATA 6b)

Pediatric weight-based dosing (for reference only — ATA 6c/6d):

• Newborn: 10–15 mcg/kg/day (standard/low-dose regimens 5–10 mcg/kg/d; high-dose regimens 10–15 mcg/kg/d)
• ~1 year old: 4–6 mcg/kg/day
• Adolescents: 2–4 mcg/kg/day
• Adult (post-maturation): ~1.6 mcg/kg/day

3.3 Titration & Monitoring Schedule

ATA 4b: Dose adjustments of 12.5–25 mcg/day are made up or down depending on whether TSH is high or low. Recheck TSH 4–6 weeks after ANY dose change (LT4 reaches steady state and TSH reaches its nadir by then). Once the target TSH is reached: recheck TSH in 4–6 months, then YEARLY to confirm stability.

Trigger	Action
Starting LT4 or any dose change	Recheck TSH in 4–6 weeks
TSH at goal, newly stable	Recheck TSH in 4–6 months, then annually
Large change in body weight, aging, new pregnancy	Reassess dose requirement — recheck TSH 4–6 weeks after any resulting change
Switch in LT4 brand/generic product	Recheck TSH at steady state (ATA 3d)
New or discontinued estrogen/androgen therapy	Recheck TSH at steady state — these alter LT4 requirement (ATA 3e)
Hospitalized, elevated TSH found	Consider institution/adjustment of LT4; factor in absorption, timing, comorbidities (ATA 20a)

💡 Clinical Pearls — Dosing & Titration
– 12.5–25 mcg is the standard dose-adjustment increment — this is board-exam gold.
– Never re-check TSH before 4–6 weeks post-change — checking early gives a misleading (still-equilibrating) value and risks over-correction.
– “Start low, go slow” in cardiac patients is about minimizing angina/arrhythmia risk, not about efficacy — the eventual target TSH is the same.
– A brand/generic switch is a real, guideline-recognized reason to recheck labs — this is a key medication-reconciliation catch for pharmacists.

3.4 Deleterious Effects of Mis-dosing

ATA 4c: Excess LT4 (iatrogenic thyrotoxicosis): risk of atrial fibrillation (3-fold increase in patients >65y with TSH <0.1 mIU/L) and osteoporosis/fractures, particularly in older persons and postmenopausal women. Avoid TSH <0.1 mIU/L in these groups.

ATA 4d: Inadequate LT4: adverse lipid profile, progression of atherosclerotic cardiovascular disease, reversible cardiomyopathy in severe cases. Overt hypothyroidism should be treated to normalize TSH to reduce these risks.

Administration, Absorption & Drug Interactions

4.1 Timing of Administration

ATA 3a: Take LT4 consistently either 60 minutes before breakfast OR at bedtime (≥3 hours after the evening meal) for optimal, consistent absorption. Absorption occurs in the jejunum and ileum. A fasting (pre-breakfast) regimen tends to produce the most consistent TSH values; a bedtime regimen is a reasonable, more convenient alternative. Whatever regimen is chosen, consistency matters more than the specific time.

4.2 Medications/Supplements That Impair Absorption

ATA 3b: Where feasible, separate LT4 from other potentially interfering medications/supplements. A 4-hour separation is the traditional (though formally untested) recommendation.

Agent	Effect on LT4 absorption (evidence)
Calcium carbonate / citrate / acetate	↓ absorption (RCT/crossover data); T4 response area reduced to 58–84% depending on formulation
Ferrous sulfate (iron)	↓ absorption; TSH rose from 1.6 to 5.4 mIU/L with co-administration in a trial
Aluminum-containing antacids	↓ absorption via adsorption; case data show TSH rising from ~1 to >30 mIU/L
Sucralfate	↓ and delayed absorption (case reports + placebo-controlled data)
Bile acid sequestrants (cholestyramine, colesevelam)	Marked ↓ absorption — colesevelam reduced response area to ~4% of baseline
Phosphate binders (sevelamer, lanthanum)	↓ absorption; mean TSH ~20 mIU/L reported with sevelamer co-administration
Raloxifene	↓ absorption (case report: TSH normal → 9.4 mIU/L)
Orlistat	↓ absorption (case report: TSH 0.03 → 73 mIU/L)
Cation-exchange resins (e.g., sodium polystyrene sulfonate)	↓ absorption via drug adsorption
Proton pump inhibitors (PPI) / H2 blockers	Pharmacokinetic (AUC) studies show NO significant effect, but a retrospective chart review found ↑TSH with PPI use — conflicting evidence; monitor if clinically relevant
Ciprofloxacin	Reported interaction reducing LT4 effect (case report)
Coffee, high-fiber diet, soy protein, grapefruit-adjacent literature	↓/delayed absorption reported; separate timing where possible

4.3 Medications Altering Metabolism/Binding (Not Just Absorption)

ATA 3e: Initiation or discontinuation of estrogen or androgen therapy should be followed by reassessment of TSH at steady state, since these alter binding-protein levels (e.g., TBG) and LT4 requirement.

4.4 Gastrointestinal Conditions That Increase LT4 Requirement

ATA 3c: When LT4 dose requirements are much higher than expected, evaluate for GI disorders — H. pylori-related gastritis, atrophic gastritis, or celiac disease. Treating these conditions and then re-evaluating thyroid function/dosage is recommended.

• H. pylori gastritis: LT4 requirement up to 34% higher (2.05 vs 1.5 mcg/kg/d) vs. controls; eradication lowered TSH substantially in a nonrandomized study (30.5 → 4.2 mIU/L).
• Autoimmune atrophic gastritis: prevalent in Hashimoto’s patients (45% of those >60y in one study); parietal cell antibody titer correlates with LT4 dose requirement.
• Celiac disease: higher LT4 requirement documented in retrospective studies; gluten-free diet reduces the requirement.
• Other reported causes of ↑ requirement: lactose intolerance, intestinal giardiasis, extreme obesity (BMI >40), advancing age, and — via a different mechanism — nephrotic syndrome (urinary loss of thyroid-binding proteins).
• Bariatric/GI bypass surgery: case reports of increased requirement exist, but directly studied Roux-en-Y and other gastric bypass patients showed preserved LT4 absorption — data are mixed.

4.5 Formulation Choice

ATA 2a: Prescribe brand-name LT4, OR maintain the SAME identifiable generic formulation consistently — switching between products (brand↔generic or generic↔generic) can alter absorption and serum TSH. This is a WEAK recommendation with LOW-quality evidence in general populations, but a STRONG recommendation in frail patients, high-risk thyroid cancer patients, and pregnant patients, and STRONG with MODERATE evidence in early childhood hypothyroidism.

ATA 2b/3d: Gel capsules or liquid LT4 formulations may have a more favorable absorption profile in specific situations (concomitant coffee, PPI use, post-bariatric surgery) based on limited/preliminary data — not a blanket recommendation, but a reasonable option when malabsorption is suspected and cannot otherwise be resolved. ANY change in LT4 product/formulation should trigger a follow-up TSH at steady state.

⚠ Pharmacist Watchouts — Absorption & interactions
– This is the #1 pharmacist catch: an unexplained rise in TSH is a medication-reconciliation problem until proven otherwise — screen for new calcium, iron, PPI, bile acid sequestrant, phosphate binder, or a pharmacy-driven generic substitution before assuming disease progression.
– Counsel patients explicitly: take LT4 alone, same time daily, and wait ≥4 hours before/after calcium, iron, antacids, or bile-acid sequestrants.
– If a pharmacy-level generic substitution occurred (very common with insurance formulary changes), flag it in the chart and recommend a TSH recheck at steady state — don’t assume “generic = generic.
– “In a patient on unexpectedly high LT4 doses, consider ordering H. pylori testing or celiac serology work-up rather than just escalating the dose indefinitely.

💡 Clinical Pearls — Absorption
– The 4-hour separation rule is a practical, guideline-endorsed convention — even though it hasn’t been formally tested as “4 hours” specifically, it’s the standard counseling point.
– PPI interaction with LT4 is a classic point of confusion: PK studies say “no effect,” but real-world/ retrospective data suggest otherwise — treat it as a possible interaction clinically even though the mechanism is unproven.
– Fiber, soy, and coffee are under-recognized absorption disruptors — always ask about diet/supplement timing during medication review, not just Rx-to-Rx interactions.

Levothyroxine in Special Populations

Elderly (ATA 6a)

ATA 6a: Initiate at low doses with slow titration based on TSH. Normal TSH ranges are higher in older populations (>65y), and higher serum TSH targets may be appropriate. Final LT4 dose needed is generally lower than in younger adults (decreased T4 turnover, decreased lean body mass). Elderly patients are more susceptible to thyrotoxicosis adverse effects (atrial fibrillation, osteoporotic fractures) — careful titration is essential.

Pregnancy (ATA 6b)

ATA 6b: Overt hypothyroidism in pregnancy: titrate LT4 to trimester-specific TSH targets (see Section 1.2). Check TSH every 4 weeks during the first half of pregnancy, and reassess during the second half. Women already on LT4 who become pregnant: add 2 extra doses/week as soon as pregnancy is confirmed.

• Untreated overt hypothyroidism in pregnancy is linked to: decreased fertility, miscarriage/stillbirth, hypertension, postpartum hemorrhage, preterm delivery, low birth weight, and irreversible fetal cognitive deficits.
• LC/MS-MS is the ATA-endorsed method for FT4 assay during pregnancy given interference from ↑TBG and altered protein binding with standard immunoassays.

Cardiovascular Disease (ATA 4b, 5b)

• Start 12.5–25 mcg/day; titrate slowly while monitoring for angina or new tachyarrhythmia.
• Most CAD patients can ultimately be fully treated to target TSH, especially with concurrent beta-blocker therapy.
• If full-dose LT4 cannot be tolerated due to cardiac symptoms, cardiac-directed therapy (medical or surgical) may be needed rather than permanently under-treating the hypothyroidism.

Renal / Hepatic Disease (ATA 5b)

• No LT4 dose adjustment is required for cirrhosis or renal failure per se.
• Nephrotic syndrome: large urinary losses of thyroid-binding proteins (TBG, transthyretin, albumin) can increase LT4 requirement.

Psychosocial / Mental Health Conditions (ATA 5c)

ATA 5c: Treatment goals are the same as the general population. Refer to a mental health professional if symptom severity is not explained by the degree of biochemical thyroid dysfunction, or if the mental health condition is impairing effective LT4 management.

Perceived Allergy / Excipient Intolerance (ATA 5a)

• True dye allergy is rare; can be managed with 50 mcg tablets, which are colorant-free.
• Purported lactose, acacia, or gluten intolerance is largely anecdotal, but formulations vary — switching product (including to a gel capsule) is a reasonable empiric trial.

💡 Clinical Pearls — Special Populations
– Pregnancy is a pharmacist counseling MUST: tell patients to increase their dose (2 extra doses/week) themselves the moment a pregnancy test is positive, and get labs within days — don’t wait for the next OB visit.
– In the elderly, higher “normal” TSH is expected and protective — chasing a young-adult TSH target in a frail 85-year-old can cause harm (AFib, fracture).
– “Start low, go slow” in cardiac disease is a titration philosophy, not a permanent dose ceiling — the end target TSH doesn’t change.

Hospitalized Patients, Myxedema Coma & NTIS

6.1 Non-Critically Ill Hospitalized Patients

• ATA 20a: In hospitalized (non-critical) patients with known hypothyroidism found to have elevated TSH, consider institution/adjustment of LT4 — factoring in clinical/biochemical severity, comorbidities, and administration details (dose, timing, absorption factors).
• ATA 20b: Therapeutic goal remains long-term TSH normalization at steady state. Do NOT titrate to FT4 unless TSH cannot be relied upon (e.g., post-pituitary surgery).
• ATA 20d: Before treating/increasing LT4 in a hospitalized patient, consider whether adrenal insufficiency should be excluded.

6.2 Myxedema Coma (Medical Emergency)

• ATA 21a: Route: IV levothyroxine. Loading dose 200–400 mcg IV (lower for smaller/older patients or those with CAD/arrhythmia history), then maintenance ~1.6 mcg/kg/day, REDUCED TO 75% of the calculated dose while given intravenously. Switch to oral/enteral once the patient improves clinically.
• ATA 21b: Empiric IV glucocorticoid coverage (stress dosing) MUST be given, and should PRECEDE levothyroxine administration, as part of initial therapy — untreated coexisting adrenal insufficiency can be unmasked/worsened by thyroid hormone replacement.
• ATA 21c: IV liothyronine (LT3) may be added given possible impaired peripheral T4→T3 conversion. Loading dose 5–20 mcg, then maintenance 2.5–10 mcg IV every 8 hours; use lower doses in smaller/older patients or those with CAD/arrhythmia. AVOID high LT3 doses — associated with increased mortality.
• ATA 21d: Therapeutic endpoints: improved mental status, cardiac function, and pulmonary function — not simply normalized labs. Measure thyroid hormones every 1–2 days. Failure of TSH to trend down, or failure of thyroid hormones to improve, may prompt increasing LT4 and/or adding LT3; a high T3 is an indication to decrease therapy.

Supportive care in myxedema coma (per guideline discussion): treat hypothermia, hypoventilation, hyponatremia, and hypoglycemia; obtain a serum cortisol prior to (or concurrent with) starting empiric glucocorticoids; give empiric broad-spectrum antibiotics if sepsis is in the differential.

⚠ Pharmacist Watchouts — Myxedema coma
– Sequence matters: glucocorticoids BEFORE or WITH levothyroxine, never levothyroxine alone first — this is a classic exam and real-world safety point.
– Don’t push high-dose LT3 — mortality signal with excessive T3 levels means “more is not better” here.
– The degree of TSH elevation does NOT reliably reflect severity in myxedema coma (wide range reported) — treat the clinical picture, not just the number.

6.3 Nonthyroidal Illness Syndrome (NTIS) — Do NOT Treat

ATA 22a/22b: In critically ill adults with NTIS (low T3, possibly low TSH/T4 without pre-existing thyroid disease), thyroid hormone replacement (LT4 or LT3) is NOT currently recommended — this reflects adaptive physiology, and treatment has not shown benefit.

ATA 22c: In hospitalized patients with cardiac dysfunction (e.g., advanced heart failure) and low T3, routine LT3 replacement is likewise not established as beneficial outside of research protocols; small studies (e.g., LT3 infusion in dilated cardiomyopathy) show short-term hemodynamic improvement, but robust outcome data are lacking.

💡 Clinical Pearls — Hospital Setting
– Myxedema coma order-set check:
(1) IV hydrocortisone/glucocorticoid stress dose first or concurrently,
(2) IV LT4 loading dose (reduced for elderly/cardiac),
(3) daily maintenance at 75% of the oral equivalent while IV,
(4) consider low-dose IV LT3,
(5) supportive care for temperature/glucose/sodium/ventilation.
– A low TSH in the ICU without a prior thyroid history is NTIS until proven otherwise — resist starting LT4.
– A rising TSH in a KNOWN hypothyroid patient who is critically ill is different — that patient should be maintained (or have their dose adjusted), because untreated true hypothyroidism can itself precipitate critical illness.

Combination LT4/LT3 Therapy & Key Clinical Trials

7.1 Bottom Line on Combination Therapy

The ATA guideline reviewed multiple RCTs (parallel and cross-over design) comparing combination LT4/LT3 therapy or desiccated thyroid extract to LT4 monotherapy. The overwhelming majority of trials showed NO significant difference (NS) in outcomes/TSH between combination therapy and LT4 alone; a few showed a preference signal for combination therapy in blinded cross-over designs, but total patient numbers in the positive trials were small (~128 across 4 trials) and standardization/validation of “preference” as an endpoint is lacking.

Selected combination-therapy trials (very brief PICO)

Study design	Population	Intervention vs Comparator	Result
Parallel, blinded, 15 wks	141 autoimmune hypothyroidism pts	LT4/LT3 (10:1 or 5:1 ratio) vs usual LT4	TSH lower with 5:1 ratio group; otherwise comparable
Cross-over, blinded, 5 wks	35 pts, mixed autoimmune/thyroid cancer	Usual T4 minus 50 mcg + T3 12.5 mcg vs usual T4	No significant difference (NS)
Parallel, blinded, 12 months	697 randomized (573 completed), primary hypothyroidism, no thyroid cancer	Usual T4 minus 50 mcg + T3 10 mcg vs usual T4	LT4/LT3 combo > LT4 alone (largest trial in the table)
Cross-over, blinded, 10 wks	110 randomized (101 completed), mixed etiology, no thyroid cancer	Usual T4 minus 50 mcg + T3 10 mcg vs usual T4	LT4/LT3 combo > LT4 alone
Randomized, double-blind cross-over, 16 wks	78 randomized (70 completed), mixed etiology, no thyroid cancer	Desiccated thyroid extract (1mg per 1.667 mcg usual T4) vs usual LT4	Thyroid extract > LT4 (patient-reported outcome trial)

(“NS” = no statistically significant difference between arms; most trials in the guideline’s full table set — 9 of the ~11 combination trials — reported NS results.)

Other pivotal trials cited for LT4 monotherapy dosing practice

Trial	Population	Intervention vs Comparator	Result
Roos et al. 2005, RCT (ref 227)	Adults with primary hypothyroidism	Full calculated starting dose vs. low-dose/gradual titration	Full-dose start was safe (dobutamine stress echo/ergometry at 12 & 24 wks showed no cardiac harm in CV-disease-free patients); faster biochemical normalization, no difference in symptom resolution time
Alexander et al. 2004, NEJM (ref 228)	Pregnant women with pre-existing hypothyroidism	Observed LT4 requirement over gestation	Demonstrated timing/magnitude of increased LT4 requirement during pregnancy — basis for the “2 extra doses/week” recommendation
Carswell et al. 2013 (ref 107)	30 children with primary hypothyroidism (20 CH, 11 autoimmune), TSH >100	Brand-name LT4 (8 wks) vs generic LT4 (8 wks), cross-over	TSH significantly lower on brand vs generic (p=0.002); difference concentrated in congenital hypothyroidism subgroup — basis for the “don’t switch products” recommendation, especially in severe/pediatric disease
Ladenson et al. 1982 (ref 604)	Primary hypothyroidism, mean TSH ~80 mIU/L	100 mcg IV LT4 daily, no loading dose	TH levels normalized in 4 days; significant TSH/clinical improvement within a week — supports myxedema coma IV dosing approach

💡 Clinical Pearls — Combination therapy & trials
– LT4 monotherapy remains standard of care.
– Combination LT4/LT3 is NOT routinely recommended — most trials show no benefit, and the few positive signals come from small, methodologically limited studies.
– If a patient insists combination therapy “changed their life,” this is a real (if inconsistently reproduced) finding in some trials — but it is not yet an evidence-based standard practice; discuss the mixed evidence rather than dismissing the patient’s experience outright.
– Full starting dose vs. slow titration is NOT an efficacy question — it’s a cardiac-safety question.
– Roos 2005 showed full dosing is safe once CV disease is excluded, not that slow titration is inferior.

Quick-Reference Summary Sheet

8.1 One-Page Dosing Algorithm

• STEP 1 — Confirm diagnosis: TSH ↑ (± FT4 ↓). If central hypothyroidism suspected (pituitary/hypothalamic disease, TSH inappropriately normal/low with low FT4) → use FT4 for monitoring, not TSH.
• STEP 2 — Select starting dose: ~1.6 mcg/kg/day full replacement (healthy adult) OR 25–50 mcg/day (mild/SCH) OR 12.5–25 mcg/day (elderly/CAD — start low, go slow).
• STEP 3 — Counsel on administration: same time daily, 60 min before breakfast OR at bedtime (≥3h after last meal); separate ≥4h from calcium, iron, antacids, bile acid sequestrants, phosphate binders.
• STEP 4 — Recheck TSH in 4–6 weeks. Adjust dose by 12.5–25 mcg increments up/down based on TSH.
• STEP 5 — Repeat step 4 until target TSH reached (0.4–4.0 mIU/L general adult target; adjust for age/pregnancy/central disease).
• STEP 6 — Once stable: TSH at 4–6 months, then annually. Recheck sooner if: dose change, product switch, new pregnancy, major weight change, new interacting medication, or new GI diagnosis (celiac, H. pylori, etc.).

8.2 Cut-off Labs at a Glance

Parameter	Value	Meaning/Action
TSH (general adult target)	0.4–4.0 mIU/L	Standard therapeutic target for primary OH
TSH treatment threshold (SCH)	>10 mIU/L	Treatment generally reasonable
TSH overtreatment red flag	<0.1 mIU/L	↑ AFib and fracture risk, especially elderly/postmenopausal — reduce dose
TSH recheck interval after dose change	4–6 weeks	Time to steady state
TSH recheck interval once stable	4–6 months, then yearly	Confirm long-term stability
Elderly TSH upper limit (healthy, >age-adjusted)	≈7.5 mIU/L (97.5th percentile)	Higher targets may be appropriate in old age
Pregnancy TSH (1st / 2nd / 3rd trimester)	0.1–2.5 / 0.2–3.0 / 0.3–3.0 mIU/L	Trimester-specific — recheck q4 weeks in first half of pregnancy

⚠ Pharmacist Watchouts

• Sequence in myxedema coma: glucocorticoids before/with LT4 — never LT4 alone first.
• Do not treat NTIS/sick euthyroid labs in the ICU with thyroid hormone unless the patient has a pre-existing hypothyroidism diagnosis.
• Any unexplained rise in TSH = medication reconciliation red flag first (new calcium/iron/PPI/bile acid sequestrant/phosphate binder, pharmacy generic switch, new estrogen/androgen, or poor adherence) before assuming disease progression.
• Never recheck TSH before 4–6 weeks post any dose or product change — premature labs mislead titration.
• Pregnancy: counsel patients to self-increase dose (2 extra doses/week) the moment pregnancy is confirmed, and get TSH checked promptly — don’t wait for the next scheduled visit.
• Elderly and cardiac patients: start low, go slow — but don’t under-treat indefinitely; the target TSH doesn’t change, only the pace.
• Discourage compounded T3 protocols and unsupervised desiccated thyroid dosing changes — real risk of iatrogenic thyrotoxicosis.
• In hospitalized patients about to start/increase LT4, make sure adrenal insufficiency has been considered/excluded.
• An unexpectedly high LT4 requirement should prompt an absorption/GI work-up (H. pylori, celiac, atrophic gastritis) rather than open-ended dose escalation.
• Brand-to-generic or generic-to-generic switches are NOT automatically safe from a TSH-stability standpoint — this is especially critical in pregnancy, thyroid cancer, and pediatric/severe congenital hypothyroidism.

💡 Clinical Pearls

8.4 Weekly Clinical Pearls Recap

• TSH is the primary diagnostic AND monitoring tool in primary hypothyroidism; FT4 takes over only in central hypothyroidism.
• Standard dose-adjustment increment: 12.5–25 mcg; standard recheck interval: 4–6 weeks after change, then 4–6 months, then yearly once stable.
• Full weight-based starting dose ≈1.6 mcg/kg/day; go low (12.5–25 mcg) and slow in the elderly/cardiac patients.
• Absorption interactions (calcium, iron, PPIs, bile acid sequestrants, phosphate binders, sucralfate, antacids) are the most common, most fixable cause of a suddenly “resistant” TSH.
• GI disease (H. pylori, celiac, atrophic gastritis) can dramatically raise LT4 requirement — think of this before escalating doses indefinitely.
• LT4 monotherapy remains standard of care; combination LT4/LT3 lacks consistent trial support and is not routine practice.
• Myxedema coma = IV LT4 (± IV LT3, avoiding high doses) + empiric IV glucocorticoids BEFORE/WITH LT4 + supportive care.
• NTIS in the critically ill (no prior thyroid disease) should not be treated with thyroid hormone.
• Overtreatment (TSH <0.1) risks AFib and fractures; undertreatment risks dyslipidemia, atherosclerosis progression, and reversible cardiomyopathy — both directions carry real harm.
• Maintain the same LT4 formulation whenever possible; treat any product switch as a trigger for a follow-up TSH.